Clinical Trial Update: SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating stereotactic body radiotherapy for oligo-residual non-small cell lung cancer after prior treatment with PD-1/PD-L1 immune…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fudan University | Conditions: NSCLC Stage IV | Phase 2 | Status: RECRUITING